Related Experiment Videos
Luteal phase support in assisted reproductive technology
Recai Pabuccu1, Munire Erman Akar
1Department of Obstetrics and Gynecology, Gulhane Military Medical Academy, Ankara, Turkey. rpabuccu@hotmail.com
Current Opinion in Obstetrics & Gynecology
|May 5, 2005
Summary
Luteal phase defects are common in assisted reproduction. Progesterone is the preferred luteal phase support, offering increased pregnancy rates, unlike human chorionic gonadotropin which risks ovarian hyperstimulation syndrome.
Area of Science:
- Reproductive Endocrinology
- Infertility Treatments
Background:
- Luteal phase defects are prevalent in in-vitro fertilization (IVF) stimulation protocols.
- Mechanisms include supraphysiological estradiol, reduced luteinizing hormone, corpus luteum inhibition, and hormonal asynchrony.
Purpose of the Study:
- To review luteal support options in assisted reproduction.
- To provide an evidence-based overview of current luteal support strategies.
Main Methods:
- Review of current literature on luteal phase support in assisted reproduction.
- Evidence-based analysis of available luteal support options.
Main Results:
- Gonadotropin-releasing hormone agonist use can cause luteal phase defects.
- Luteal phase support with human chorionic gonadotropin or progesterone increases pregnancy rates.
- Progesterone is preferred over human chorionic gonadotropin due to lower risk of ovarian hyperstimulation syndrome.
Conclusions:
- Progesterone is the preferred agent for luteal phase support in assisted reproduction.
- Intramuscular progesterone may offer better outcomes than vaginal administration.
- Optimal progesterone dose, route, and duration require further research.